Nirsevimab

Nirsevimab is a monoclonal antibody designed for the prevention of respiratory syncytial virus (RSV) infections in infants and young children. It is specifically engineered to provide passive immunity by targeting the RSV fusion (F) protein, which is essential for the virus's ability to infect host cells.

Mechanism of Action

Nirsevimab works by binding to the RSV F protein, thereby neutralizing the virus and preventing it from entering and infecting human cells. This mechanism is similar to that of other monoclonal antibodies used in infectious disease prevention, such as Palivizumab, but Nirsevimab has been optimized for a longer half-life, allowing for less frequent dosing.

Clinical Development

Nirsevimab has undergone several phases of clinical trials to evaluate its safety, efficacy, and pharmacokinetics. These trials have demonstrated that Nirsevimab is effective in reducing the incidence of RSV-related hospitalizations and medical visits in infants.

Indications

Nirsevimab is indicated for the prevention of RSV infections in infants and young children, particularly those who are at high risk for severe RSV disease, such as premature infants, infants with congenital heart disease, and those with chronic lung disease.

Administration

Nirsevimab is administered via intramuscular injection. The dosing schedule is designed to provide protection throughout the RSV season, which typically lasts from late fall to early spring in temperate climates.

Side Effects

Common side effects of Nirsevimab include injection site reactions, fever, and rash. Serious adverse events are rare but may include hypersensitivity reactions.

Comparison with Other Treatments

Nirsevimab offers several advantages over existing RSV prophylactic treatments, such as Palivizumab, including a longer duration of action and potentially fewer injections required over the RSV season.

Related Pages

• Respiratory syncytial virus
• Monoclonal antibody
• Palivizumab
• Congenital heart disease
• Chronic lung disease

See Also

• Immunoprophylaxis
• Infectious disease
• Pediatrics

External Links

-